Casdin Capital’s Solid Biosciences SLDB Stock Holding History

Casdin Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-775,000	Closed	-$2.87M	–	40
2025 Q1	$2.87M	Buy	+775,000	New	+$3.32M	0.23%	32

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Casdin Capital's SLDB Position: Q2 2025 in Review

Casdin Capital sold out of Solid Biosciences (SLDB) in Q2 2025, closing a stake of 775,000 shares — an estimated $2.87M sold.

Casdin Capital first reported a position in SLDB in Q1 2025 and held it in 1 quarter. The position peaked at $2.87M in Q1 2025. 114 funds tracked by Wall St. Rank hold SLDB as of Q2 2025.

Casdin Capital reported no remaining Solid Biosciences position as of Q2 2025 after selling out during the quarter.
Casdin Capital sold 775,000 Solid Biosciences shares in Q2 2025, an estimated $2.87M.
Casdin Capital first reported a position in Solid Biosciences in Q1 2025 and held it in 1 quarter.
Casdin Capital's Solid Biosciences position peaked at $2.87M in Q1 2025.
114 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2025.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.